Lorlatinib

Manufactured by Active Motif

Lorlatinib is a laboratory reagent manufactured by Active Motif. It is a small molecule inhibitor that targets the ALK (Anaplastic Lymphoma Kinase) protein. This product is intended for research use only.

Automatically generated - may contain errors

Lab products found in correlation

Ceritinib, by Active Motif (2 mentions) Cabozantinib, by Active Motif (2 mentions) Trametinib, by Active Motif (1 mentions) Sb202190, by Cell Signaling Technology (1 mentions) Tae684, by Chemietek (1 mentions) Sb239063, by Merck Group (1 mentions) Foretinib, by Adooq (1 mentions) Pha 665752, by Bio-Techne (1 mentions) Alectinib, by Active Motif (1 mentions) Azd4547, by Selleck Chemicals (1 mentions)

2 protocols using lorlatinib

Compound Acquisition for Cell Experiments

Check if the same lab product or an alternative is used in the 5 most similar protocols

Crizotinib (PF-02341066) was obtained from ShangHai Biochempartner; cabozantinib (XL184), ceritinib (LDK378), lorlatinib (PF-06463922), trametinib (GSK1120212) from ActiveBiochem; foretinib from AdooQ Bioscience; brigatinib from Sellek; radicicol and rotenone from Cayman Chemical; 17-AAG (17-N-Allylamino-17-demethoxygeldanamycin) and GDC-0941 from LC Laboratories; TAE684 from ChemieTek; SB202190 from Cell Signaling Technology; SB239063 from Sigma; and cycloheximide and doxycycline hyclate from Nacalai Tesque. Each compound was prepared in dimethyl sulfoxide (DMSO), ethanol (WAKO) or distilled water for cell culture experiments.

Ogura H., Nagatake-Kobayashi Y., Adachi J., Tomonaga T., Fujita N, & Katayama R. (2017). TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. Scientific Reports, 7, 5519.

+ Open protocol

+ Expand

Small Molecule Inhibitor Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ceritinib, alectinib, lorlatinib, cabozantinib, and zoligratinib were purchased from ActiveBiochem. Crizotinib, brigatinib, and infigratinib were purchased from Biochempartner. AZD4547 was purchased from Selleck, and PHA665752 was purchased from Tocris Bioscience.

Sakashita T., Yanagitani N., Koike S., Low S., Takagi S., Baba S., Takeuchi K., Nishio M., Fujita N, & Katayama R. (2022). Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer. Cancer Science, 113(11), 3888-3900.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!